Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Placebo Controlled, Double Blind Dose Escalation Study Of The Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, And Immunogenicity Of A Single Intravenous Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease

NCT00455000 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00455000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00455000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Placebo Controlled, Double Blind Dose Escalation Study Of The Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, And Immunogenicity Of A Single Intravenous Dose Of PF-04360365 In Adults With Mild To Moderate Alzheimer's Disease
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2007
Completion date
September 30, 2009
Enrollment
37 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease